Compare Suncor Energy Inc. (SU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Viatris Inc — how do they compare? Suncor Energy Inc. trades at $70.57 (market cap $82.76B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Suncor Energy Inc. is far larger — about 4.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Viatris Inc for 57 Days on average.
| SU | VTRS | |
|---|---|---|
Market Cap | $82.76B | $20.03B |
Volume | 3,832,959 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $71.87 | $18.27 |
52-Week Low | $38.17 | $9.74 |
Typical Hold Time | 57 Days | 57 Days |
Enterprise Value | $89.29B | $32.15B |
Dividend Yield | 2.39% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $68.14, down 0.12% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 12.98, ROE of 19.25%, and consistent earnings beats in recent quarters. Recent news highlights strategic asset sales and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings. Cash flow trends show operational strength with $12.78B from operations in 2025.
SU presents a compelling value opportunity with attractive valuation metrics and robust shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The company's integrated model and international revenue diversification provide stability, though investors should monitor execution under new leadership and global energy market conditions.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
